2017
Smoking cessation and outcome after ischemic stroke or TIA
Epstein KA, Viscoli CM, Spence JD, Young LH, Inzucchi SE, Gorman M, Gerstenhaber B, Guarino PD, Dixit A, Furie KL, Kernan WN, Bladin C, Davis S, Wijeratne T, Levi C, Parsons M, Brodtmann A, Ng S, Archer J, Delcourt C, Winder T, Berger L, Boulanger J, Chan R, Spence J, Durocher A, Mackey A, Verreault S, Minuk J, Penn A, Shuaib A, Cote R, Selchen D, Bayer N, Sweet M, Malik S, Stotts G, Griewing B, Soda H, Weinhardt R, Berrouschot J, Stoll A, Witte O, Günther A, Bodechtel U, Schminke U, Hobohm C, Hetzel A, Lambeck J, Wartenberg K, Huttner H, Dittrich R, Nabavi D, Gröschel K, Thomalla G, Rosenkranz M, Jander S, Meisel A, Ludolph A, Althaus K, Huber R, Lorenz M, Tanne D, Merzlyak O, Bornstein N, Telman G, Lampl Y, Streifler J, Weller B, Ifergane G, Wirgin Y, Carolei A, Toni D, Stanzione P, Micieli G, Agnelli G, Caso V, Gandolfo C, Comi G, Consoli D, Rasura M, Di Lazzaro V, Dixit A, Jupp B, Shaw L, Salih I, Esisi B, Power M, Strain W, Elyas S, Manawadu D, Kalra L, O'Brien E, Warburton E, Chatterjee K, Hargroves D, Blight A, Moynihan B, Markus H, Macleod M, Broughton D, Rodgers H, Hlaing T, Muir S, Sajid M, Bath P, Price C, Sekaran L, Vahidassr D, Muir K, McIlmoyle J, Datta P, Davey R, Langhorne P, Stott D, Datta P, England T, Muhidden K, O'Connell J, Majmudar N, Schindler J, Clark W, Sethi P, Rordorf G, Kleindorfer D, Silliman S, Gorman M, Kelly M, Singleton L, Meyer B, Jackson C, Walker J, Ehtisham A, Goodpasture H, Wang D, Fayad P, Cordina S, Naritoku D, Chiu D, Lukovits T, Goddeau R, Clark‐Arbogast R, Leigh R, Wityk R, Pettigrew L, Tayal A, Jarouse J, Friday G, Sen S, Kim A, Johnston S, Elkins J, Barrett A, Leira E, Kelly A, Burgin S, Rempe D, Jacoby M, Hughes D, Majersik J, Skalabrin E, Lee J, Hsu C, Sundararajan S, Slivka A, Minagar A, Alicic R, Geraghty M, Kase C, Lansberg M, Albers G, Dietrich D, Hanna J, Gentile N, Santiago F, Katzan I, Ching M, Sawyer, Warwick T, Yilmaz E, Pedelty L, Schneck M, Coull B, Solenski N, Johnston K, Lee V, Prabhakaran S, Johnson M, Silverman I, Salgado M, Birkhahn R, Strawsburg R, Altafullah I, Cohen D, Zweifler R, Lee Kwen P, Hammer M, Vora N, Tietjen G, Albakri E, Dandapani B, Jickling G, Verro P, Roller M, Hughes R, Simpson J, Vidic T, Lash S, Sigsbee B, Rosenbaum D, Fonzetti P, Fleck J, Goldszmidt A, Alexandrov A, Halsey J, Hart R, Sattin J, Kumar S, Book D, Torbey M, Poock J, King M, Graham G, Sung G, Mirsen T, Dromerick A, Runheim A, Jackson C, Feen E, Reichwein R, Waters M, Amory C, Bernardini G, Bell R, Diamond B, Rosenbaum D, Palestrant D, Segal A, Burger K, Schwartz R, Mitsias P, Kramer J, Kramer J, Robbins D, Silver B, Easton J, Feldmann E, Rymer M, Dorssom J, Ali L, Ovbiagele B, Kirshner H. Smoking cessation and outcome after ischemic stroke or TIA. Neurology 2017, 89: 1723-1729. PMID: 28887378, PMCID: PMC5644463, DOI: 10.1212/wnl.0000000000004524.Peer-Reviewed Original ResearchConceptsMyocardial infarctionIschemic strokeIndex eventProspective observational cohort studyInsulin Resistance InterventionHistory of hypertensionObservational cohort studyDiastolic blood pressureHistory of strokeCoronary artery diseaseTime of randomizationTobacco use historySignificant health benefitsRecurrent strokeNondiabetic menCohort studyCurrent smokersTrial cohortArtery diseaseBlood pressurePrimary outcomeIRIS trialStroke trialsCigarette smokingSmoking cessation
2012
Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: Results from the DIAD study
Tandon S, Wackers F, Inzucchi SE, Bansal S, Staib LH, Chyun DA, Davey JA, Young LH. Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: Results from the DIAD study. Diabetes And Vascular Disease Research 2012, 9: 124-130. PMID: 22228772, DOI: 10.1177/1479164111431470.Peer-Reviewed Original ResearchMeSH KeywordsAgedAsymptomatic DiseasesCanadaCardiovascular DiseasesDiabetes ComplicationsDiabetes Mellitus, Type 2FemaleHumansIncidenceKaplan-Meier EstimateMaleMass ScreeningMiddle AgedMyocardial Perfusion ImagingPredictive Value of TestsPrognosisProspective StudiesRisk AssessmentRisk FactorsSex FactorsTime FactorsUnited StatesConceptsType 2 diabetesMyocardial perfusion imagingCardiovascular outcomesStress myocardial perfusion imagingAsymptomatic Diabetics (DIAD) studyBetter cardiac outcomesHigh-risk womenCoronary artery diseaseHigh-risk menDetection of ischemiaMPI abnormalitiesAsymptomatic patientsAsymptomatic menCardiac eventsCardiac outcomesArtery diseaseAsymptomatic womenAbnormal screeningDiabetic studyPerfusion imagingDIAD studyWomenMenDiabetesOutcomes
2010
CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIAL
Bansal S, Wackers F, Inzucchi S, Young L, Chyun D. CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIAL. Journal Of The American College Of Cardiology 2010, 55: a141.e1325. DOI: 10.1016/s0735-1097(10)61326-5.Peer-Reviewed Original Research
2009
Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes : The DIAD Study: A Randomized Controlled Trial
Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE, Investigators F. Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes : The DIAD Study: A Randomized Controlled Trial. JAMA 2009, 301: 1547-1555. PMID: 19366774, PMCID: PMC2895332, DOI: 10.1001/jama.2009.476.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseType 2 diabetesNonfatal myocardial infarctionAsymptomatic coronary artery diseaseMyocardial perfusion imagingCardiac event rateMyocardial infarctionCardiac deathMPI defectsCardiac outcomesEvent ratesScreened groupArtery diseaseSymptoms of CADRadionuclide myocardial perfusion imagingAsymptomatic Diabetics (DIAD) studyHigh cardiac riskLow event ratesPositive predictive valueDetection of ischemiaPrimary medical preventionCoronary revascularizationDiabetes clinicIdentifies patientsControlled Trials
2008
Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart
Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, Young LH. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008, 451: 578-582. PMID: 18235500, DOI: 10.1038/nature06504.Peer-Reviewed Original ResearchMeSH KeywordsAMP-Activated Protein KinasesAnimalsAntigens, Differentiation, B-LymphocyteCoronary Artery DiseaseEnzyme ActivationGenetic Predisposition to DiseaseGenotypeGlucoseHistocompatibility Antigens Class IIHumansHypoxiaMacrophage Migration-Inhibitory FactorsMiceMultienzyme ComplexesMyocardial IschemiaMyocardial Reperfusion InjuryMyocardiumPolymorphism, GeneticPromoter Regions, GeneticProtein Serine-Threonine KinasesRatsSignal TransductionConceptsIschemic heartMacrophage migration inhibitory factorLower MIF levelsCoronary artery diseaseIschemic heart diseaseMigration inhibitory factorPotential risk markerMIF levelsArtery diseaseRisk markersHeart diseaseIschemic stressCytokine MIFInhibitory factorGlucose uptakePotential drug targetsDiseaseHeartDrug targetsCellular stress responseAMPKMaster regulatorNew studiesPatientsAtherosclerosis
2007
Screening for Coronary Artery Disease in Patients With Diabetes
Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ. Screening for Coronary Artery Disease in Patients With Diabetes. Diabetes Care 2007, 30: 2729-2736. PMID: 17901530, DOI: 10.2337/dc07-9927.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCoronary artery diseaseArtery diseaseCardiovascular diseaseHigh-risk coronary artery diseaseStable coronary artery diseaseCoronary artery calcium scoringAdditive survival benefitIntensive medical managementRecognition of diabetesCVD risk reductionPercutaneous coronary revascularizationStrong clinical suspicionAmerican Diabetes AssociationType 2 diabetesClinical trial resultsCost of diabetesAsymptomatic patientsAtherosclerotic burdenCoronary revascularizationCardiac eventsClinical suspicionCoronary atherosclerosisDiabetic populationSurvival benefitAsymptomatic atherosclerosis
2005
Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome
Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome. Metabolic Syndrome And Related Disorders 2005, 3: 147-173. PMID: 18370723, DOI: 10.1089/met.2005.3.147.Peer-Reviewed Original ResearchType 2 diabetesMetabolic syndromeBeta-cell functionCardiovascular effectsEndothelial dysfunctionVascular reactivityInsulin sensitivityFuture cardiovascular eventsAdverse clinical eventsCoronary artery diseasePositive cardiovascular effectsCardiovascular disease burdenPotential adverse eventsProgression of diabetesInsulin-sensitizing effectsCardiovascular eventsCardiovascular outcomesAdverse eventsCardiovascular riskArtery diseaseGlycemic controlClinical eventsInsulin resistanceDisease burdenRisk factorsAMPK – A pivotal rheostat in the control of cardiac metabolism
Miller E, Russell R, Li J, Young L. AMPK – A pivotal rheostat in the control of cardiac metabolism. Drug Discovery Today Disease Mechanisms 2005, 2: 93-100. DOI: 10.1016/j.ddmec.2005.05.008.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMyocardial stress responseRegulation of AMPKProtein kinaseCentral regulatorStress responseAMPKNon-metabolic actionsCoronary artery diseaseNovel cardioprotective strategiesType 2 diabetesPotential novel approachArtery diseaseCardioprotective strategiesCardiac metabolismMetabolic actionsPossible roleKinaseRheostatRegulatorRegulationMetabolismDiabetesDisease
2004
Abnormal heart rate response to adenosine infusion is associated with silent myocardial ischemia in asymptomatic patients with diabetes mellitus
Sudhakar S, Chyun D, Young L, Inzucchi S, Davey J, Wackers F. Abnormal heart rate response to adenosine infusion is associated with silent myocardial ischemia in asymptomatic patients with diabetes mellitus. Journal Of Nuclear Cardiology 2004, 11: s20. DOI: 10.1016/j.nuclcard.2004.06.064.Peer-Reviewed Original ResearchHeart rate responseSilent myocardial ischemiaLarge myocardial perfusion defectsMyocardial perfusion defectsLarger perfusion abnormalityAsymptomatic patientsNegative predictive valuePerfusion abnormalitiesMyocardial ischemiaPerfusion defectsAdenosine infusionRate responsePredictive valueAbnormal heart rate responseBlunted heart rate responseHigh negative predictive valueLower heart rate responseCoronary artery diseaseMyocardial perfusion abnormalitiesDetection of ischemiaMales 53Autonomic neuropathyArtery diseaseDiabetes mellitusPoor outcomeCardiac Abnormalities in Diabetic Patients With Neuropathy
Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chyun DA, Law G, Wackers FJ, Young LH. Cardiac Abnormalities in Diabetic Patients With Neuropathy. Diabetes Care 2004, 27: 448-454. PMID: 14747227, DOI: 10.2337/diacare.27.2.448.Peer-Reviewed Original ResearchMeSH KeywordsAldehyde ReductaseBenzothiazolesCardiac OutputDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic NeuropathiesDouble-Blind MethodEnzyme InhibitorsExercise TestFemaleHeartHeart Conduction SystemHeart RateHumansMaleMiddle AgedPhthalazinesPlacebosStroke VolumeThiazolesVentricular Function, LeftConceptsLeft ventricular ejection fractionDiabetic patientsARI treatmentCardiac outputStroke volumeCardiac abnormalitiesAldose reductase inhibitorExercise left ventricular ejection fractionAbnormal heart rate variabilityDiastolic peak filling rateAsymptomatic cardiac abnormalitiesGated radionuclide ventriculographyMaximal bicycle exercisePlacebo-treated subjectsDiastolic filling rateVentricular ejection fractionCoronary artery diseaseValvular heart diseasePeak filling rateExercise cardiac outputLV stroke volumeHeart rate variabilityBlinded treatmentInsulin useArtery disease
2003
Diagnosis of CAD in patients with diabetes: Who to evaluate
Young LH, Jose P, Chyun D. Diagnosis of CAD in patients with diabetes: Who to evaluate. Current Diabetes Reports 2003, 3: 19-27. PMID: 12643142, DOI: 10.1007/s11892-003-0048-3.BooksConceptsCoronary artery diseaseCardiac testingDiabetic patientsDiagnosis of CADNoninvasive cardiac testingManagement of patientsCAD screeningAsymptomatic ischemiaAsymptomatic patientsSymptomatic patientsArtery diseaseCardiac catheterizationRisk stratificationPatientsAccurate diagnosisDiagnosisAppropriate useDiabetesEffective diagnosisCurrent controversiesRecent informationRevascularizationCatheterizationIschemiaClinicians
2000
Effect of hyperinsulinemia on myocardial amino acid uptake in patients with coronary artery disease
McNulty P, Jacob R, Deckelbaum L, Young L. Effect of hyperinsulinemia on myocardial amino acid uptake in patients with coronary artery disease. Metabolism 2000, 49: 1365-1369. PMID: 11079831, DOI: 10.1053/meta.2000.9510.Peer-Reviewed Original ResearchConceptsBranched-chain amino acidsIschemic heart diseaseMyocardial uptakeArterial plasmaHeart diseaseChronic ischemic heart diseaseCoronary artery diseasePlasma BCAA concentrationsEffect of hyperinsulinemiaMyocardial glucose uptakeNet myocardial uptakeEuglycemic insulin infusionsNet glutamate uptakeOxidative energy substratesPossible salutary effectsBCAA uptakeMyocardial utilizationEuglycemic hyperinsulinemiaArtery diseaseInsulin levelsBCAA concentrationsInsulin infusionAmino acid uptakeAnabolic effectsCardiovascular disease
1995
Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance.
McNulty P, Louard R, Deckelbaum L, Zaret B, Young L. Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance. Circulation 1995, 92: 2151-6. PMID: 7554195, DOI: 10.1161/01.cir.92.8.2151.Peer-Reviewed Original ResearchConceptsMyocardial protein degradationInsulin infusionCardiovascular diseaseMyocardial protein synthesisInsulin resistancePhenylalanine balanceMyocardial hypertrophyWhole-body glucose metabolismCoronary artery diseaseIschemic heart diseasePlasma insulin concentrationNet phenylalanine balanceWhole-body carbohydrate metabolismEffect of insulinMyocardial protein metabolismArtery diseaseAcute hyperinsulinemiaProtein synthesisHeart diseaseInsulin concentrationsPlasma concentrationsAntiproteolytic actionHyperinsulinemiaGlucose metabolismConstant infusion
1991
Myocardial protein turnover in patients with coronary artery disease. Effect of branched chain amino acid infusion.
Young LH, McNulty PH, Morgan C, Deckelbaum LI, Zaret BL, Barrett EJ. Myocardial protein turnover in patients with coronary artery disease. Effect of branched chain amino acid infusion. Journal Of Clinical Investigation 1991, 87: 554-560. PMID: 1991838, PMCID: PMC296343, DOI: 10.1172/jci115030.Peer-Reviewed Original ResearchConceptsBranched-chain amino acid infusionCoronary artery diseaseAmino acid infusionProtein turnoverBCAA infusionProtein synthesisArtery diseaseAcid infusionAmino acidsMyocardial protein turnoverCardiac double productCoronary blood flowPlasma insulin levelsMyocardial oxygen consumptionHuman heartProtein degradationNegative protein balanceEssential amino acidsMyocardial balanceInsulin levelsDouble productPhenylalanine balanceAnabolic effectsMyocardial uptakePostabsorptive patients